PP 001

Drug Profile

PP 001

Latest Information Update: 27 Feb 2015

Price : $50

At a glance

  • Originator 4SC Discovery
  • Developer Panoptes Pharma
  • Class Small molecules
  • Mechanism of Action Interferon gamma inhibitors; Interleukin-17 inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Infectious conjunctivitis; Uveitis

Most Recent Events

  • 10 Feb 2015 PP 001 licensed to Laboratoires Leurquin-Mediolanum for marketing in two European countries
  • 04 Oct 2013 PP 001 is available for licensing as of 04 Oct 2013. http://panoptes.at/
  • 26 Sep 2013 Preclinical trials in Uveitis in Austria (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top